Biotricity, a remote patient monitoring company, has received the US Food and Drug Administration (FDA)-clearance for its cardiac monitoring device, Biotres. The company claims Biotres is the first device to provide continuous 3 channel recording of electrocardiogram (ECG) data.
The wearable holder patch records real-time ECG data for early detection of cardiac arrhythmias focusing on lower-risk patients. The technology allows cardiologists to access collected cardiac data for warning signs and integrates with existing health systems, facilitating cardiac prevention and monitoring. It can be worn continuously for 48 hours after a single charge and will be available to the users from April 2022.
The device is expected to expand Biotricity’s product portfolio and market reach from USD 1 billion to USD 5.7 billion. The FDA approval comes after the company raised non-dilutive financing of USD 12 million in December 2021.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.